Critical Outcome Technologies Inc.

Critical Outcome Technologies Inc.

November 14, 2008 09:03 ET

Critical Outcome Technologies Inc. to Meet With Prospective Partners for COTI-2 at BIO Europe 2008

LONDON, ONTARIO--(Marketwire - Nov. 14, 2008) - Critical Outcome Technologies Inc. (TSX VENTURE:COT), announced today the Company will meet with several prospective partners for its lead oncology drug candidate COTI-2 at BIO Europe 2008 taking place November 17-19 in Manheim, Germany.

Critical Outcome Technologies Inc. (COTI) has arranged meetings at BIO Europe 2008 with decision makers from several major pharmaceutical organizations including follow-on meetings with previous contacts. The primary objective of the meetings is to present new data on COTI-2 including its novel and potentially first in class mechanism of action and to further explore licensing opportunities regarding its ongoing development. "Several pharmaceutical organizations have shown significant interest in licensing COTI-2 and this new data will stimulate further discussions as we continue to evaluate our options pertaining to a licensing arrangement," said Mr. Michael Cloutier, CEO of COTI.

COTI has also scheduled several meetings at BIO Europe 2008 to discuss both co-development opportunities related to existing COTI small molecules and also lead discovery collaborations that would be comparable in scope to its ongoing projects with other global pharmaceutical companies. "We remain focused on developing financially viable revenue streams using our proprietary technology, CHEMSAS®, as we concurrently develop our own novel drug candidates," said Dr. Wayne Danter, President and CSO of COTI.

COTI will be represented at BIO Europe 2008 by Mr. Michael Cloutier, CEO, Dr. Wayne Danter, President and CSO and Mr. Michael Barr, Director of Business Development and Marketing.

Notice to Readers

Information contained in this press release may contain certain statements which constitute "forward-looking statements" within the meaning of the Securities Act (Ontario) and applicable securities laws. Specifically, the statement "novel and potentially first in class mechanism of action (MOA)" is a forward-looking statement. This statement was based upon research test results on the molecule, an understanding of the current therapies both in use and in trials for cancer and includes patent research and the socializing of the data package with a significant number of Pharmaceutical companies of various sizes. Forward-looking statements, by their nature, are not guarantees of future performance and are based upon management's current expectations, estimates, projections and assumptions. COTI operates in a highly competitive environment that involves significant risks and uncertainties which could cause actual results to differ materially from those anticipated in these forward-looking statements. Management of COTI considers the assumptions on which these forward-looking statements are based to be reasonable, but as a result of the many risk factors, cautions the reader that actual results could differ materially from those expressed or implied in these forward-looking statements. Information in this press release should be considered accurate only as of the date of the release and may be superseded by more recent information disclosed in later press releases, filings with the securities regulatory authorities or otherwise.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI's business is focused on the discovery and preclinical development of libraries of novel, optimized lead molecules for the treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds under active development including; small cell lung cancer, HIV integrase inhibitors, acute myelogenous leukemia in adults, multiple sclerosis and colorectal cancer.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information